Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-10-08

Clinical Trial Update: Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating how blood phenylalanine levels influence Kuvan response in phenylketonuria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KUVAN (Sapropterin dihydrochloride)

Snippet

Sponsor: University of Miami | Conditions: Phenylketonuria | Phase 2 | Status: COMPLETED | Results posted: 2019-10-08